OLD National Bancorp IN Sells 19,971 Shares of Bristol Myers Squibb Company $BMY

OLD National Bancorp IN trimmed its stake in Bristol Myers Squibb Company (NYSE:BMY) by 9.1% during the 4th quarter, Holdings Channel reports. The firm owned 200,632 shares of the biopharmaceutical company’s stock after selling 19,971 shares during the quarter. OLD National Bancorp IN’s holdings in Bristol Myers Squibb were worth $10,822,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of BMY. Darwin Wealth Management LLC purchased a new position in Bristol Myers Squibb in the second quarter worth $25,000. Harbor Capital Advisors Inc. boosted its holdings in shares of Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 313 shares in the last quarter. KERR FINANCIAL PLANNING Corp bought a new position in shares of Bristol Myers Squibb during the 3rd quarter valued at about $35,000. JPL Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb during the 3rd quarter valued at about $36,000. Finally, Beacon Financial Strategies CORP bought a new stake in Bristol Myers Squibb in the 4th quarter worth approximately $38,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Atrium Therapeutics announced it earned a $15M development milestone payment from Bristol Myers Squibb under their cardiovascular collaboration — a sign the partnered program advanced to a pre-agreed development candidate milestone, which de-risks that asset and validates BMS’s pipeline investments. Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb
• Positive Sentiment: Barclays reportedly initiated (or reiterated) a Buy on BMY — analyst upgrades/Buy ratings can lift the stock by increasing demand and signaling confidence in growth/earnings trajectory. Bristol-Myers Squibb (BMY) Receives a Buy from Barclays
• Positive Sentiment: Buy-side and independent outlets (Zacks, MSN) are publishing bullish/tactical takes — calling BMY a value/momentum name vs. peers and highlighting its cheaper valuation and improving earnings outlook, which supports longer-term investor interest. Here’s Why Bristol Myers Squibb (BMY) is a Strong Value Stock
• Neutral Sentiment: Bernstein kept a Hold on BMY — a Hold is not a fresh negative but tempers upside from upgrades and signals that some analysts remain cautious on near-term catalysts. Bernstein Remains a Hold on Bristol-Myers Squibb (BMY)
• Neutral Sentiment: Earnings are expected this week — scheduled quarterly results are a primary near-term catalyst (guidance and product trends will matter most given last quarter’s EPS miss and FY2026 guidance). Investors are positioning ahead of the print. Bristol Myers Squibb (BMY) Expected to Announce Quarterly Earnings on Thursday
• Neutral Sentiment: Geronimo Power’s new solar project will supply power under PPAs that include Bristol Myers Squibb — a sustainability/operational-cost item that is positive long-term but unlikely to move the stock materially near-term. Geronimo Power commences operations at 270MW Blevins Solar Project
• Negative Sentiment: Some market commentaries and sector pieces flagged downbeat forecasts or questioned certain pharma names — negative analyst notes or skeptical headlines can pressure BMY, especially when coupled with prior EPS misses or generic/competitive risks. 1 Unpopular Stock That Should Get More Attention and 2 We Question

Insider Activity at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the transaction, the executive vice president owned 159,248 shares in the company, valued at $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.05% of the stock is currently owned by corporate insiders.

Bristol Myers Squibb Price Performance

Shares of Bristol Myers Squibb stock opened at $59.04 on Thursday. The firm has a market cap of $120.54 billion, a PE ratio of 17.13, a price-to-earnings-growth ratio of 0.17 and a beta of 0.27. The company’s fifty day simple moving average is $59.74 and its two-hundred day simple moving average is $53.95. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The firm had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. During the same quarter in the prior year, the company posted $1.67 earnings per share. The business’s revenue for the quarter was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities analysts expect that Bristol Myers Squibb Company will post 6.28 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.3%. Bristol Myers Squibb’s payout ratio is 73.04%.

Wall Street Analyst Weigh In

A number of brokerages have commented on BMY. Citigroup increased their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. Scotiabank reaffirmed a “sector perform” rating and issued a $60.00 price objective (up from $53.00) on shares of Bristol Myers Squibb in a research note on Friday, January 9th. HSBC lifted their target price on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a research report on Tuesday, March 17th. Royal Bank Of Canada began coverage on shares of Bristol Myers Squibb in a research report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price target for the company. Finally, Bank of America reduced their price objective on Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating on the stock in a research note on Thursday, April 9th. Eight equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $61.31.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.